Explore Gut Repair & IBD Gut barrier, inflammatory balance, antioxidant, and cellular support
doi: 10.3389/fnut.2025.1686777 Received 15 August 2025 Revised 15 November 2025 Accepted 28 November 2025 Published 12 January 2026 Volume 12 - 2025 Edited by Andrea Orellana-Manzano, Escuela Superior Politcnica del Litoral (ESPOL), Ecuador Reviewed by Paulina Cerda Opazo, Autonomous University of Chile, Chile Aliakbar Fazaeli, Ardabil University of Medical Sciences, Iran Updates Copyright 2026 Garutti, de Scordilli, Alberti, Mazzeo, Michelotti, Fagioli, Del Conte, Casirati, Caccialanza, Bartolini and Puglisi
Far in the lead is Lilly with its late-stage orforglipron, which in a June 2023 Phase II readout achieved weight loss between 9.4% and 14.7% at 36 weeks
Film-type health supplements are quickly absorbed into the body and have better effects on the human body
Drug candidates such as Etomoxir or its analogs, which inhibits CPT1A and FAO, can be developed as RT and CT sensitizers in breast cancer (Han et al., 2019)
